Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform
November 9, 2015 9:28 AM ESTOppenheimer reiterated a Perform rating on Agios Pharma (NASDAQ: AGIO) following initial data from an ongoing phase I trial of AG-120. AG-120 was generally well tolerated in advanced solid tumors including glioma, IHCC and chondrosarcoma, with no dose-limiting toxicities (DLTs) observed based on the... More
